


- 14 -

CLAIMS

1. A hybridoma cell line which produces monoclonal antibodies capable of binding to the AT₁ subtype of the angiotensin II receptor.
2. A hybridoma cell line according to claim 1 which produces monoclonal antibodies that bind specifically to amino acid residues 8-17 of the mammalian AT₁ receptor.
3. A hybridoma cell line which produces monoclonal antibodies that bind specifically to a peptide having the amino acid sequence



4. A hybridoma cell line according to claim 1 being characterised by cell line accession No. 930720117 deposited at European Collection of Animal Cell Cultures, Porton Down, UK.
5. A monoclonal antibody that binds to the AT₁ subtype of the angiotensin II receptor.
6. A monoclonal antibody according to claim 5 that binds to amino acid residues 8-17 of the mammalian AT₁ receptor.
7. A monoclonal antibody that binds specifically to a peptide having the amino acid sequence



8. Use of the monoclonal antibody according to any

09540815-033100

P26
A2

- 15 -

one of claims 5 to 7 for the detection of AT₁ subtype of angiotensin II receptor.

9. Use of the monoclonal antibody according to any one of claims 5 to 7 for the control of vaso-constriction.

10. Use of the monoclonal antibody according to any one of claims 5 to 7 for the control of uterine contractions.

11. A diagnostic test kit comprising the monoclonal antibody of according to any one of claims 5 to 7 attached to a detectable label.

12. A method of treating hypertension comprising administering a therapeutic effective amount of a monoclonal antibody according to any one of claims 5 to 7.

13. A method of controlling uterine contractions comprising administering a therapeutic effective amount of a monoclonal antibody according to any one of claims 5 to 7.

Doc 92
92404046
004423